Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,400 shares of the company on 12-31-2024. This trade was reported by Quiver Quantitative using data from a ...
Greenwich LifeSciences, Inc. is a late-stage biotech company focusing on developing an immunotherapy treatment for breast cancer. Their pipeline includes one drug, GLSI-100, currently in a phase 3 ...
Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01. Discover the top trade setups and strategies ...
If you want to know who really controls Greenwich LifeSciences, Inc. (NASDAQ:GLSI), then you'll have to look at the makeup of its share registry. We can see that individual insiders own the lion's ...
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning the Company and its directors’ and officers’ possible violations of state laws ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results